Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Clinical Investigation

• Publication date

  2000-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI8688PMID 10749568PMCID PMC377482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nephrogenic diabetes insipidus.

  2012cited by this paper
• Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis.

  1999cited by this paper
• O-Glycosylation of the V2 vasopressin receptor.

  1999cited by this paper
• 6-Aminohexanoic Acid as a Chemical Chaperone for Apolipoprotein(a)*

  1999cited by this paper
• The molecular basis of nephrogenic diabetes insipidus

  1998cited by this paper
• 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.

  1998cited by this paper
• The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities

  1998cited by this paper
• Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones.

  1998cited by this paper
• Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype.

  1998cited by this paper
• Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators*

  1997cited by this paper
• Prion Protein Aggregation Reverted by Low Temperature in Transfected Cells Carrying a Prion Protein Gene Mutation*

  1997cited by this paper
• An X-linked NDI mutation reveals a requirement for cell surface V2R expression.

  1997cited by this paper
• Reconstitution of mutant V2 vasopressin receptors by adenovirus-mediated gene transfer. Molecular basis and clinical implication.

  1997cited by this paper
• Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists.

  1997cited by this paper
• Biochemical basis of partial nephrogenic diabetes insipidus phenotypes.

  1997cited by this paper
• Structural Instability of a Constitutively Active G Protein-coupled Receptor

  1997cited by this paper
• Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.

  1996cited by this paper
• Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co‐expressed receptor polypeptide.

  1996cited by this paper
• Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors.

  1996cited by this paper
• Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

  1996cited by this paper
• Influence of molecular and chemical chaperones on protein folding.

  1996cited by this paper
• Functional characterization of five V2 vasopressin receptor gene mutations.

  1996cited by this paper
• Membrane Targeting and Determination of Transmembrane Topology of the Human Vasopressin V2 Receptor*

  1996cited by this paper
• A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist.

  1995cited by this paper
• Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus.

  1995cited by this paper
• Many naturally occurring mutations of myelin proteolipid protein impair its intracellular transport

  1994cited by this paper
• Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation

  1991cited by this paper
• Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes.

  1991cited by this paper
• Mutant alpha subunits of Gi2 inhibit cyclic AMP accumulation.

  1991cited by this paper
• Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.

  1991cited by this paper
• Mutant α subunits of Gi2 inhibit cyclic AMP accumulation

  1991cited by this paper
• Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

  1990cited by this paper
• The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum.

  1987cited by this paper
• Use of eukaryotic expression technology in the functional analysis of cloned genes.

  1987cited by this paper
• Binding of a specific ligand inhibits import of a purified precursor protein into mitochondria

  1986cited by this paper
• Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

  1986cited by this paper
• Assembly of asparagine-linked oligosaccharides.

  1985cited by this paper

• Mechanisms governing GPCR anterograde transport

  2025cites this paper
• Sustained Gαs signaling mediated by vasopressin type 2 receptors is ligand dependent but endocytosis and β-arrestin independent.

  2025cites this paper
• Improvement of Mutant Galactose-1-Phosphate Uridylyltransferase (GALT) Activity by FDA-Approved Pharmacochaperones: A Preliminary Study

  2025cites this paper
• Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning

  2025influential citation
• Folding, misfolding, and regulation of intracellular traffic of G protein-coupled receptors involved in the hypothalamic-pituitary-gonadal axis.

  2025cites this paper
• Mutant protein chemical rescue: From mechanisms to therapeutics

  2025cites this paper
• Beneficial Handling of Molecular Chaperones (Chaperonotherapy) in Glioblastoma and Neuroblastoma: Novel Therapeutic Targets or Potential Agents?

  2025cites this paper
• A small molecule stabilizer rescues the surface expression of nearly all missense variants in a GPCR

  2025cites this paper
• Antagonists Enhance Cell-Surface Expression of Mammalian Odorant Receptors

  2025cites this paper
• Disorders of Water Imbalance

  2025cites this paper
• Functional Characterisation and cAMP-Mediated Rescue of a Novel Truncating AVPR2 Mutation Causing Nephrogenic Diabetes Insipidus.

  2025cites this paper
• International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance)

  2024cites this paper
• Progress in the development of Modulators targeting Frizzleds.

  2024cites this paper
• Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors

  2024cites this paper
• Decoding Polycystin-1's G-Proteolytic Site: Implications for Cell Interactions and Autosomal Dominent Polycystic Kidney Disease Pathogenesis

  2024cites this paper
• Chaperone therapy: Stabilization and enhancement of endogenous and exogenous lysosomal enzymes.

  2024cites this paper
• Endoplasmic Reticulum Stress in Bronchopulmonary Dysplasia: Contributor or Consequence?

  2024cites this paper
• Treatment of congenital disorders of glycosylation: An overview.

  2024cites this paper
• Segregation of nascent GPCRs in the ER-to-Golgi transport by CCHCR1 via direct interaction.

  2024cites this paper
• Genome-wide pan-GPCR cell libraries accelerate drug discovery

  2024cites this paper
• Therapeutic development approaches to treat haploinsufficiency diseases: restoring protein levels.

  2024cites this paper
• A practical synthesis of nitrone-derived C5a-functionalized isofagomines as protein stabilizers to treat Gaucher disease

  2024cites this paper
• Patologías del receptor V2 de la vasopresina: diabetes insípida nefrógena congénita y síndrome de antidiuresis inapropiada nefrógena

  2024cites this paper
• G protein-coupled receptor (GPCR) gene variants and human genetic disease

  2024cites this paper
• Pathologies du récepteur V2 de la vasopressine : diabète insipide néphrogénique congénital et syndrome d’antidiurèse inappropriée néphrogénique

  2023cites this paper
• The cellular pathways that maintain the quality control and transport of diverse potassium channels.

  2023cites this paper
• V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology

  2023cites this paper
• Tubular Diseases and Stones Seen From Pediatric and Adult Nephrology Perspectives.

  2023cites this paper
• Structural basis for the allosteric modulation of rhodopsin by nanobody binding to its extracellular domain

  2023cites this paper
• Exploring the “misfolding problem” by systematic discovery and analysis of functional-but-degraded proteins

  2023cites this paper
• Clinical, Genetic and Functional Characterization of a Novel AVPR2 Missense Mutation in a Woman with X-Linked Recessive Nephrogenic Diabetes Insipidus

  2022cites this paper
• Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones

  2022cites this paper
• Pharmacological chaperones for the oxytocin receptor increase oxytocin responsiveness in myometrial cells

  2022cites this paper
• Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin

  2022cites this paper
• Assessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems

  2022cites this paper
• Mechanistic insights into the primary and secondary alterations of renal ion and water transport in the distal nephron

  2022cites this paper
• Human C1orf27 protein interacts with α2A-adrenergic receptor and regulates its anterograde transport

  2022cites this paper
• Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases

  2022cites this paper
• Cell-trafficking impairment in disease-associated LPA6 missense mutants and a potential pharmacoperone therapy for autosomal recessive woolly hair/hypotrichosis.

  2022cites this paper
• Mutations in melanocortin-4 receptor: From fish to men.

  2022cites this paper
• Genetic basis of nephrogenic diabetes insipidus.

  2022cites this paper
• Trafficking-defective mutant PROKR2 cycles between endoplasmic reticulum and Golgi to attenuate endoplasmic reticulum stress

  2022cites this paper
• Cell-to-cell variations in subcellular localisation of V2R are independent of its expression level

  2022cites this paper
• Functional Rescue of Inactivating Mutations of the Human Neurokinin 3 Receptor Using Pharmacological Chaperones

  2022cites this paper
• Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones

  2022cites this paper
• Role of misfolding in rare enzymatic deficits and use of pharmacological chaperones as therapeutic approach.

  2021cites this paper
• Pharmacogenomics of GPCR genes in type 2 diabetes and obesity

  2021cites this paper
• Clinical and Functional Characterization of a Novel Mutation in AVPR2 Causing Nephrogenic Diabetes Insipidus in a Four-Generation Chinese Family

  2021cites this paper
• Individual cells traffic the Vasopressin 2 Receptor to their cell surface with different success

  2021cites this paper
• Misfolded G Protein-Coupled Receptors and Endocrine Disease. Molecular Mechanisms and Therapeutic Prospects

  2021cites this paper
• A joint method for the screening of pharmacological chaperones for phenylalanine hydroxylase.

  2021cites this paper
• Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators

  2021cites this paper
• Familial DI and Genetic Workup

  2021cites this paper
• Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus

  2021cites this paper
• Vasopressin Type 2 Receptor Agonists and Antagonists

  2021cites this paper
• Pharmacological Chaperones | Encyclopedia

  2020cites this paper
• Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells.

  2020cites this paper
• Epithelial Ion Channel Folding and ER-Associated Degradation (ERAD)

  2020cites this paper
• GENETICS IN ENDOCRINOLOGY Pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus.

  2020cites this paper
• Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation

  2020cites this paper
• AQP2: Mutations Associated with Congenital Nephrogenic Diabetes Insipidus and Regulation by Post-Translational Modifications and Protein-Protein Interactions

  2020cites this paper
• 4PBA Restores Signalling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with PAH.

  2020cites this paper
• Rescue of Function of Mutant Luteinising Hormone Receptors with Deficiencies in Cell Surface Expression, Hormone Binding, and Hormone Signalling

  2020cites this paper
• Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations

  2020influential citation
• Assistance for Folding of Disease-Causing Plasma Membrane Proteins

  2020cites this paper
• Cellular high-throughput screening

  2020cites this paper
• Renal Aquaporins in Health and Disease

  2020cites this paper
• Image-based screen capturing misfolding status of Niemann-Pick type C1 identifies potential candidates for chaperone drugs

  2020cites this paper
• Nephrogenic Diabetes Insipidus.

  2019cites this paper
• An Antifungal for Antidiuresis?

  2019cites this paper
• Modulation of proteostasis and protein trafficking: a therapeutic avenue for misfolded G protein-coupled receptors causing disease in humans.

  2019cites this paper
• New insights into the transcriptional regulation of aquaporin-2 and the treatment of X-linked hereditary nephrogenic diabetes insipidus

  2019cites this paper
• Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics.

  2019cites this paper
• Diabetes insipidus

  2019cites this paper
• Small-scale approach for precrystallization screening in GPCR X-ray crystallography

  2019cites this paper
• Therapeutic strategies for diseases caused by loss-of-function mutations in G protein-coupled receptors.

  2019cites this paper
• Dissociation of natriuresis and diuresis by oxytocin molecular forms in rats

  2019cites this paper
• Encoding the β-Arrestin Trafficking Fate of Ghrelin Receptor GHSR1a: C-Tail-Independent Molecular Determinants in GPCRs.

  2019cites this paper
• Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis

  2019cites this paper
• Screening of Chemical Libraries Using a Yeast Model of Retinal Disease

  2019cites this paper
• Diseases caused by mutations in luteinizing hormone/chorionic gonadotropin receptor.

  2019cites this paper
• Chapter X Pharmacoperones for misfolded gonadotropin receptors

  2018influential citation
• hCALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia

  2018cites this paper
• Nephrotic Syndrome and Glomerular Basement Membrane: Genetic Defect of the Laminin α5 Chain

  2018cites this paper
• Glycosylation and dimerization of the human δ-opioid receptor polymorphic variants

  2018cites this paper
• NK1R/5‐HT1AR interaction is related to the regulation of melanogenesis

  2018influential citation
• Role of EPS15 Homology Domain-Containing Protein 4 (EHD4) in the Kidney

  2018cites this paper
• Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.

  2018cites this paper
• Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders

  2018cites this paper
• Pharmacoperones for Misfolded Gonadotropin Receptors.

  2018cites this paper
• Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.

  2018cites this paper
• Fluorogenic Probing of Membrane Protein Trafficking.

  2018cites this paper
• Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

  2018cites this paper
• Characterization of vasopressin V 2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model

  2017cites this paper
• Relax, Cool Down and Scaffold: How to Restore Surface Expression of Folding-Deficient Mutant GPCRs and SLC6 Transporters

  2017cites this paper
• Biased Agonist Pharmacochaperones: Small Molecules in the Toolbox for Selectively Modulating GPCR Activity

  2017cites this paper
• Pharmacological chaperones for the misfolded melanocortin-4 receptor associated with human obesity.

  2017cites this paper
• Pharmacological Chaperones of the Dopamine Transporter: A Strategy for Increasing Function of Wild Type and Mutant Transporter

  2017influential citation
• The Posterior Pituitary

  2017cites this paper
• Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies

  2017cites this paper